---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-028637"
form_type: "8-K"
ticker: "HEPA"
cik: "0001583771"
company_name: "Hepion Pharmaceuticals, Inc."
filed_at: "2024-07-22T23:59:59+00:00"
generated_at: "2026-05-31T18:32:20.714455+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Hepion Pharmaceuticals enters definitive merger agreement with Pharma Two B Ltd., expects Q4 2024 close

## Summary
- Hepion will merge with Pharma Two B Ltd.; existing Hepion shareholders receive ordinary shares of Parent.
- Concurrent $2.9M note sale (SPA) at 116% of principal; purchasers also receive up to 19.99% of HEPA outstanding shares.
- Closing expected Q4 2024, subject to stockholder approvals, Nasdaq listing, IIA approval, and at least $8.6M cash from SPA.
- Certain Hepion stockholders entered support agreements (covering ~0.025% of shares) and 180-day lock-up agreements.

## SEC filing metadata
- accession: 0001493152-24-028637
- form_type: 8-K
- ticker: HEPA
- cik: 0001583771
- company_name: Hepion Pharmaceuticals, Inc.
- filed_at: 2024-07-22T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 2.03, 3.02, 5.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1583771/000149315224028637/0001493152-24-028637-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1583771/000149315224028637/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-028637
- JSON: https://secwatch.observer/filing/0001493152-24-028637.json
- Plain text: https://secwatch.observer/filing/0001493152-24-028637.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.